Search Results
Jun 09, 2026, 21:45 ET MUST estreia a série de energia híbrida para todos os cenários na SNEC 2026
independência energética residencial com vida útil de mais de 6.000 ciclos. Para os setores comercial e industrial, os inversores de alta tensão PH11-60KL3-EU-HV (30 kW–60 kW) e as baterias HV2800 ESS (64 kWh–240 kWh) oferecem soluções escaláveis conectadas à rede, enquanto o sistema de armazenamento
More news about: Must Energy Group
Jun 09, 2026, 21:44 ET MUST presenta en SNEC 2026 su serie de inversores solares híbridos para todos los escenarios
energética de los hogares, con una vida útil de más de 6.000 ciclos. Para los sectores comercial e industrial, los inversores de alta tensión PH11-60KL3-EU-HV (30 kW-60 kW) y las baterías ESS HV2800 (64 kWh-240 kWh) ofrecen soluciones ampliables conectadas a la red, mientras que el sistema
More news about: Must Energy Group
Jun 08, 2026, 21:52 ET MUST Luncurkan Seri Energi Hibrida untuk Berbagai Skenario di SNEC 2026
hingga 15,36 kWh. Produk-produk ini menawarkan usia pakai lebih dari 6.000 siklus. Di sektor komersial dan industri, inverter voltase tinggi PH11-60KL3-EU-HV berkapasitas 30 kW hingga 60 kW dan baterai ESS HV2800 berkapasitas 64 kWh hingga 240 kWh menjadi solusi yang dapat diintegrasikan dengan
More news about: Must Energy Group
Jun 08, 2026, 20:30 ET MUST Debuts All-Scenario Hybrid Energy Series at SNEC 2026
(3.5kW–5.5kW, 3kWh–15.36kWh) address residential energy independence with 6,000+ cycle lifespans. For commercial and industrial sectors, the PH11-60KL3-EU-HV high-voltage inverters (30kW–60kW) and HV2800 ESS batteries (64kWh–240kWh) deliver scalable grid-tied solutions, while the ESG industrial
More news about: Must Energy Group
Jun 08, 2026, 20:30 ET MUST ra mắt dòng giải pháp năng lượng lai cho mọi kịch bản ứng dụng tại SNEC 2026
toán tự chủ năng lượng cho hộ gia đình với tuổi thọ hơn 6.000 chu kỳ. Đối với lĩnh vực thương mại và công nghiệp, các biến tần điện áp cao PH11-60KL3-EU-HV (30kW–60kW) và pin lưu trữ năng lượng HV2800 (64kWh–240kWh) cung cấp các giải pháp hòa lưới có khả năng mở rộng. Trong khi đó, hệ
More news about: Must Energy Group
Jun 03, 2026, 00:03 ET Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
https://www.ncbi.nlm.nih.gov/books/NBK431049/11 Hackett KL, et al. Impaired functional status in primary Sjögren's syndrome. Arthritis Care Res (Hoboken). 2012 Nov;64(11):1760-4.12 Meijer JM,
More news about: Johnson & Johnson
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Kelun-Biotech
May 30, 2026, 20:00 ET 榮登《柳葉刀》主刊！蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗一線治療 PD-L1 陽性 NSCLC III期重磅結果發表
，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞並於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞周期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及台灣)以外的所有地區開發、使用、制造及商業化蘆康沙妥珠單抗(
More news about: 科倫博泰
May 30, 2026, 00:30 ET 2026 ASCO | 蘆康沙妥珠單抗(sac-TMT) III期OptiTROP-Lung05研究成果於ASCO口頭報告和《柳葉刀》同步發佈
，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及台灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥珠單抗(
More news about: 科倫博泰
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Kelun-Biotech
May 21, 2026, 20:00 ET Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Kelun-Biotech
May 21, 2026, 20:00 ET 2026 ASCO | 科倫博泰2項 註冊研究入選2026 ASCO非小細胞肺癌口頭報告專場
，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及臺灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥珠單抗(
More news about: 科倫博泰
May 21, 2026, 10:04 ET Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Kelun-Biotech
May 21, 2026, 10:04 ET 第六項註冊臨床獲陽性結果！蘆康沙妥珠單抗(sac-TMT)對比化療一線治療晚期TNBC III期臨床達到PFS主要終點
腫瘤細胞，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。於2022年5月，公司授予默沙東（美國新澤西州羅威市默克公司的商號）在大中華區（包括中國內地、香港、澳門及臺灣）以外的所有地區開發、使用、製造及商業化蘆康沙妥
More news about: 科倫博泰
May 20, 2026, 23:07 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--CCRN, EEX, BLD, and QXO
CCRN) related to its sale to KL Criss Cross Intermediate, LLC. Under the terms of the proposed transaction Cross Country shareholders are expected to receive $13.25 per share in cash.Click
More news about: Monteverde & Associates PC
May 08, 2026, 06:47 ET 蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗一線治療PD-L1陽性NSCLC的sNDA獲NMPA受理
，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及臺灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥珠單抗(
More news about: 科倫博泰
May 08, 2026, 06:40 ET The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Kelun-Biotech
May 04, 2026, 08:32 ET HUAWEI WATCH FIT 5 Serisi: Giyilebilir Teknolojide Modern Şıklığı Yeniden Tanımlıyor
content:https://www.prnewswire.com/news-releases/huawei-watch-fit-5-serisi-giyilebilir-teknolojide-modern-kl-yeniden-tanmlyor-302761323.html
More news about: HUAWEI
Apr 23, 2026, 06:16 ET KL Rahul x Paul & Shark: The SS26 capsule signed by the renowned Indian athlete
partnership we have built with KL Rahul, and the creation of this dedicated capsule is a clear expression of it. Through this project, we bring together Paul & Shark's core values of heritage, craftsmanship, a passion for travel, and the balance of elegance and performance, which KL Rahul embodies perfectly,
More news about: Paul & Shark
Apr 21, 2026, 20:53 ET Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Kelun-Biotech
Apr 21, 2026, 20:28 ET 2026 ASCO | 科倫博泰3項研究成果入選2026美國臨床腫瘤學會年會口頭彙報
藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及臺灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥珠單抗(s
More news about: 科倫博泰
Apr 13, 2026, 20:00 ET Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Kelun-Biotech
Apr 13, 2026, 20:00 ET 双双入選2026 SGO口頭報告：蘆康沙妥珠單抗(sac-TMT)兩項婦科腫瘤研究成果發佈
物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞並於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其實現旁觀者效應，即殺死鄰近的腫瘤細胞。於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及臺灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥珠單抗(sac
More news about: 科倫博泰
Apr 13, 2026, 09:15 ET Sceye gennemfører historisk 12-dages stratosfærisk flyvning på 6.400 mil og baner vejen for et nyt lag af infrastruktur til gavn for menneskeheden
til at forberede os på og reagere på skovbrande eller andre naturkatastrofer."Under Sceyes SE2-flyvning, der blev iværksat den 25. marts 2026 kl. 08:26 MT fra New Mexico, gjorde Sceye følgende:Den var i drift i over 12 dage, startede fra New Mexico og afsluttede missionen
More news about: Sceye
Apr 07, 2026, 08:30 ET Strategic Demand for Rare Earth Elements Intensifies Across Energy, Defense and Technology Sectors
Technical Director, discuss the significance of the initial assay results at Rift.Apex Critical Metals Corp. (CSE: APXC) (OTCQX: APXCF) (FWB: KL9) ("Apex" or the "Company"), a Canadian mineral exploration company focused on the identification and development of critical and strategic metals,
More news about: Market News Updates